SABCS 2023
YiR in EBC #1: New data in HER2+ and Immunotherapy in HR+ and TNBC
KATHERINE, PHERGain (ASCO23), KEYNOTE-522, ALEXANDRA/IMpassion030, KEYNOTE-756 (ESMO&SABCS), CheckMate-7FL
SABCS 2023
YiR in EBC #1: New data in HER2+ and Immunotherapy in…
SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304, Oxford analyses ASCO23, monarchE, NATALEE, POSITIVE (SABCS22 &23)
SABCS 2023
YiR in EBC #2: De-escalating therapy in locoregional…
BEGONIA, SAFIR02-Breast, HER2CLIMB02, KATHERINE, COMPASS, DESTINY-Breast -01, -02, -03, TULIP, monarcHER
SABCS 2023
YiR in ABC #1: Exciting new data for first line mTNBC,…
SONIA, monarch3, PARSIFAL-long, INAVO120, RIGHT-Choice, PALMIRA, EMERALD, CAPItello291
SABCS 2023
YiR in ABC #2: New data on treatment in metastatic HR+…
DESTINY-Breast 04, TROPiCS-02, TROPION-Breast01
SABCS 2023
YiR in ABC #3: Exciting new data on ADCs in HR+ breast…
KEYNOTE-756
SABCS 2023
Prediction of pCR in KEYNOTE-756
NATALEE
SABCS 2023
Final iDSF analysis in NATALEE
CheckMate756, KEYNOTE-756, POSITIVE
SABCS 2023
SABCS23 highlights in early breast cancer
KEYNOTE-756
SABCS 2023
KEYNOTE-756 - Subgroup analysis
CheckMate 7FL
SABCS 2023
CheckMate7FL - Biomarker
CheckMate 7FL, KEYNOTE-756
SABCS 2023
Hope with CPI for luminal breast cancer
monarchE
SABCS 2023
cTDNA analyses in monarchE
NATALEE
SABCS 2023
An enrichment of therapy options in the endocrine…
ADAPTcycle
SABCS 2023
ADAPTcycle - endocrine response
SURVIVE, SURVIVE HERoes
SABCS 2023
Change in the standard of follow-up care?
KATHERINE
SABCS 2023
T-DM1 in post-neoadjuvant therapy now also with…
KATHERINE
SABCS 2023
KATHERINE: OS improvement in HER2+ eBC
ALEXANDRA/IMpassion030
SABCS 2023
Immunotherapy for early TNBC must be neoadjuvant
POSITIVE
SABCS 2023
Pregnancy despite endocrine therapy in HR+ breast…
SABCS 2023
Pregnancy after BC is safe - also in germline BRCA+ pts
POSITIVE
SABCS 2023
Importance of the onco-fertility discussion
SABCS 2023
Anthtracyclines in EBC: to give or not to give?
CheckMate756, KEYNOTE-756, POSITIVE
SABCS 2023
SABCS23 evidenzia il cancro al mammario in fase precoce
SABCS 2023
Gravidanza dopo la diagnosi di carcinoma mammario è…
KATHERINE
SABCS 2023
KATHERINE : amélioration de la survie globale dans le…
monarchE
SABCS 2023
Análisis de cTDNA en monarchE
POSITIVE
SABCS 2023
Importância da discussão sobre onco-fertilidade
MONARCH 3
SACBS 2023
MONARCH 3 shows clinically relevant OS-benefit without…
PARSIFAL-LONG
SABCS 2023
Letrozole + palbo as effective as fulvestrant + palbo
INAVO120
SASBCS 2023
PIK3CA-inhibitor: positive results in Phase III
MONARCH 3
SABCS 2023
Is OS important?
INAVO120
SABCS 2023
Promising data for the PIK3CA-inhibitor inavolisib
FOENIX-MBC2 study
SABCS 2023
Fulvestrant + futibatinib interesting for FGFR1…
CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant in HR+ HER2-…
PARSIFAL-LONG
SABCS 2023
Long follow-up of CDK4/6i
MONARCH 3
SABCS 2023
Final OS analysis in MONARCH 3
MONARCH 3
SABCS 2023
Does abemciclib lead to improved OS survival in the 1st…
DESTINY-Breast08
SABCS 2023
T-DXd + endocrine therapy interesting for HR+ HER2low…
MONARCH 3
SABCS 2023
SABCS23 highlights in metastatic breast cancer
PARSIFAL-LONG
SABCS 2023
OS benefit with fulvestrant/letrozole + palbocilib is…
TROPION-Breast01
SABCS 2023
Dato-Dxd achieves PFS
HER2CLIMB-02
SABCS 2023
New potential backbone for tucatinib in mHER2+ BC
HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1 interesting for specific patients
ASPIRE
SABCS 2023
Effective, chemo-free combination for triple-positive…
HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1: Possible role in the contemporary…
AVIATOR/TBCRC045
SABCS 2023
Avelumab appears to be effective in HER2+ mBC
HER2CLIMB-02
SABCS 2023
Efficacy of tucatinib confirmed, but unclear for which…
KEYLYNK-009
SABCS 2023
KEYLYNK-009: Pembrolizumab + olaparib a well-tolerated…
SENOMAC
SABCS 2023
Axillary surgery de-escalation
PREFERABLE-EFFECT
SABCS 2023
Physical acitivity improves QoL in advanced BC
SENOMAC
SABCS 2023
Positive sentinel lymph node after mastectomy
PREFERABLE-EFFECT
SABCS 2023
Metastatic patients can and must exercise
SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Rethinking management of the axilla
ICARO
SABCS 2023
Isolated tumor cells in the sentinel lymph node - does…
NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Axillary radiotherapy can be omitted in T3N1 BC pts
ADAPTcycle
SABCS 2023
Poster insights: PO4-01-10 ADAPTcycle
OLAnzaPiNE
SABCS 2023
Low-dose olanzapine more favorable in the prophylaxis…
TROPION-Breast01
SABCS 2023
Dato-Dxd consigue PFS
PREFERABLE-EFFECT
SABCS 2023
L'attività fisica migliora la qualità di vita nel…
CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant dans le cancer…
HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1: Possibile un ruolo nello scenario…
MONARCH 3
SABCS 2023
SABCS23 evidenzia nel cancro al mammario metastatico
CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant nel carcinoma…
SENOMAC
SABCS 2023
Desescalada de cirugía axilar
HER2CLIMB-02
SABCS 2023
Tukatynib skuteczny, ale czy umiemy określić jego…
NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
La radioterapia ascellare può essere omessa nelle…
INAVO120
SABCS 2023
Inhibiteur de PIK3CA: résultats positifs en phase III
SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Duże zmiany w leczeniu pachy
PARSIFAL-LONG
SABCS 2023
La supervivencia obtenida con palbociclib y…
CheckMate-7FL, Keynote-756, ALEXANDRA/IMpassio030, KEYLYNK-009
SABCS 2023
Immunotherapy and combination therapies for HR+/HER2-…
MONARCH 3
SABCS 2023
No significant OS - but what is the impact on clincial…
HER2CLIMB-02
SABCS 2023
New and good therapy options for HER2+ patients
NRG Oncology, NSABP B-51, RTOG 1304
SABCS 2023
De-escalation of radiotherapy after neoadjuvant therapy
TROPION-Breast01
SABCS 2023
Good balance between benefits and side effect - but not…
POSITIVE
SABCS 2023
Pregnancy is safe after endocrine therapy
OPBC05/EUBREAST-14R/ICARO, SENOMAC
SABCS 2023
DE-escalation of the axillary interverntion after…
Katherine
SABCS 2023
OS and final iDFS data - confirming data but risk and…
INAVO120
SABCS 2023
PI3K inihbitor Inavolisib shows improved PFS - one step…
NATALEE, monarchE
SABCS 2023
Final iDFS data - is everything clear yet?
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!